Go to Login or Register to make a submission.

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

  • The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
  • The submission file is in OpenOffice, Microsoft Word, or RTF document file format.
  • Where available, URLs for the references have been provided.
  • The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
  • The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.

Mitochondrial and Metabolic Medicine (M3) journal is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Authors should provide name, address and current email addresses of five potential expert reviewers. All articles submitted to the M3 journal are subjected to a two-tier review using our online peer review system. The preliminary review is conducted by an editor to make sure the article conforms to the requirements of the journal and research area is appropriate for the M3. The editor also ensures that the article brings new scientific knowledge to the field. In the second stage of the review process, articles are assigned to expert reviewers from the field. Following feedback of reviewers, the editor makes the final decision on acceptance of the article.


Manuscript submitted by author -> Editor Preliminary review -> Expert Peer Reviewer -> Decision to Accept/Reject by Editor -> Submission of revised manuscript by author -> Article formatting and layout -> DOI assignment -> Publication on company of scientists’ website -> Archival of published articles


Types of articles


The M3 journal will cover all aspects of mitochondrial metabolism and interconnecting cellular metabolic pathways including the normal metabolic processes and the breakdowns in primary and secondary mitochondrial and metabolic diseases and the treatment of these diseases.


The areas of interest include but are not limited to day-to-day needs of practicing mitochondrial specialists, approaches to the patient with various symptoms; case-reports, clinical ethical issues; updates on diseases and disorders; diagnostic and therapeutic approach; mechanisms at the molecular, genetic, metabolic and physiological levels underlying the metabolic diseases; office-based and practice management issues and tips; as well as health policy discussions when appropriate.


We welcome submission from all healthcare professionals who engage with mitochondrial disease patients including physicians, nurses, genetic counselors, physical/occupational therapists, social workers and everyone else.


M3 will publish:


Case report:


We will consider single cases and case series. Case reports should be concise and focus on unique manifestations or new observations of the clinical case.  A good case report should be informative, expanding a known phenotype, describing a new link to a mitochondrial mechanism, enhancing practitioner’s education and knowledge.


High quality studies should be referenced, and discussion should concentrate on novel aspects of the case with a clear message that might influence clinical practice.


Original article:


Original contribution with direct relevance to mitochondrial medicine will be accepted. We will consider hypothesis-driven studies, full-length clinical or translational science research, ethical cases or questions, diagnostic updates, therapeutic approaches including prospective, observational and retrospective studies, new management guidelines, meta-analysis and drug trials.


Editorial, commentary:


Analysis of current advances and insights into the rapidly evolving mitochondrial medicine field will be accepted. Topics such as exciting new recent research findings, broad clinical operation and practice management concerns of interest to the clinical readership are welcome. Health policy issues pertaining to diagnostic, therapeutic, social, ethical or economic aspects of mitochondrial medicine are also welcome. Some editorials and commentaries are usually invited, but we welcome unsolicited suggestions of topics/authors for consideration.


Short and full-length reviews articles:


Articles that examine the literature on a hot topic will be considered. A strong review article should be thorough and assess the quality of the available evidence, help the readers reach certain evidence-based conclusions and comment about gaps within the field. Some Review Articles are invited, but the editors welcome unsolicited submissions and suggestions of topics/authors for consideration.


Where possible, we would like the authors to make the material relevant to our international readers as well as our U.S. practitioners.


Cover letter


A cover letter should be added to your manuscript and should include the following:



  • Manuscript title

  • Manuscript classification (e.g., Case report, original article, review)

  • A statement that one author (usually the principal author) takes full responsibility for the data, the analyses and interpretation, and the conduct of the research. This author should certify that he/she has the right to publish data on behalf of all the authors.

  • A declaration that all authors have contributed and have agreed to authorship guidelines

  • A statement that the author has received consent from any participant (or their legal representative) in a clinical study and is able to produce those consents if requested by the editor.

  • A statement that the Author has received patient (or their legal representative) consent for any identifiable information used within the manuscript (i.e. Picture, or  video).


Manuscript Organization


a) Title (150 characters) The title should be concise and specific to the submitted topic. i) Authors and Affiliations Please provide each author’s names (first name, middle initial and last name) and affiliations. The corresponding author should be identified using an asterisk (*) and should note their institution’s name, address, telephone number, fax number, and email address) Common first authors should be marked with an asterisk following each of the common authors' highest academic degrees in the author byline. Identify the asterisk at the end of the same page and state, "These authors contributed equally to the manuscript."  ii) Key words: Include at least 5 search terms (key words) iii) On the title page, please also list: - the manuscript word count - the abstract word count  - the number of tables - the number of figures - Supplemental information when available.  iv) When applicable, list any study sponsor, grant support as “study funding”. State whether funding was institutional, government, industry, philanthropy or other. v) List all authors’ financial disclosures.


b) Abstract (250 words)


The abstract should briefly capture the overall essence of the manuscript without going into details of methodologies. It should be written in one paragraph and should not include many abbreviations.


c) Introduction


The introduction should consist of a brief background or literature review of the topic being discussed. Problems, controversies or probable hypothesis should be included when appropriate but need to be concise and relate to the study. The introduction should conclude with the main teaching message of the manuscript.


d) Materials and Methods


The materials and methods section should consist of enough details to allow proper understanding of the presented results and observations and to provide enough information to other clinicians and scientists to reproduce the research findings.  Although details of new methods should be included, the well-established methods can be referenced to the previous reports.


For therapeutic or diagnostic intervention (clinical trial, medication intervention, procedure, maneuver, or other clinical changes intended to benefit the patient), the methods must be clearly detailed.


Manuscript reporting on clinical trial results must state the overall question the trial was designed to answer and the proposed Classification of Evidence (I, II, III, or IV). It is important to be specific when describing the trial participant population, intervention of interest, and relevant outcome measures used


A separate section should include standard IRB protocol approvals, clinical trial registrations, and the consenting process for participants:


e) Results


The results section should provide details of all of the experiments that are required to support the conclusions of the paper. There is no specific word limit for this section, but details of experiments that are peripheral to the main thrust of the article and that detract from the focus of the article should not be included. The section may be divided into subsections, each with a concise subheading. Large datasets, including raw data, should be submitted as supplemental files; these are published online alongside the accepted article. The results section should be written in past tense.


f) Discussion


The discussion should spell out the major conclusions and interpretations of the work including some explanation on the significance of these conclusions. How do the conclusions affect the existing assumptions and models in the field? How can future research or clinical considerations build on these observations? The discussion should be concise and tightly argued. If warranted, the results and discussion may be combined into one section.


g) Acknowledgments


Individuals who contributed to the work, but do not fit the criteria for authors should be listed in the Acknowledgments, along with their contributions. You must also ensure that anyone named in the acknowledgments agrees to be so named. The Acknowledgments section is reserved for statements of gratitude or thanks. Details of the funding sources that have supported the work should be confined to the funding statement. Do not include them in the Acknowledgments.


h) References


It is the authors' responsibility that the information in each reference is complete and accurate. All references must be listed alphabetically using last names consecutively and citations of references in the text should be alphabetically arranged and identified using last name and year of publication in parenthesis (Reik, 2007; Wong et al., 2002). If you are using EndNote or Reference manager select Cell as journal style.  All references should be cited within the text.


Examples


Bruniquel, D., and Schwartz, R.H. (2003). Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat. Immunol. 4, 235–240.


Kangaspeska, S., Stride, B., Metivier, R., Polycarpou-Schwarz, M., Ibberson, D., Carmouche, R.P., Benes, V., Gannon, F., and Reid, G. (2008). Transient cyclical methylation of promoter DNA. Nature 452, 112–115.


Wong, E., Yang, K., Kuraguchi, M., Werling, U., Avdievich, E., Fan, K., Fazzari, M., Jin, B., Brown, A.M., Lipkin, M., and Edelmann, W. (2002). Mbd4 inactivation increases transition mutations and promotes gastrointestinal tumor formation. Proc. Natl. Acad. Sci. USA 99, 14937–14942.


i) Figures


M3 requires high-resolution electronic images with a minimum resolution of 600 dpi for line drawings (black and white) and 300 dpi for color or greyscale figures. All figures should be submitted either as GIF, JPG, EPS or TIFF files. Authors need to provide high-resolution images of all accepted manuscripts for final publication in MM. Figures must be generated using software such as Photoshop, Adobe Illustrator, etc. Figure legend should be self-sufficient to describe the main points for each figure to independently provide information about the figure. Each legend should have a title of no more than 15 words. We encourage authors to submit high-quality color figures to be considered for the cover of the journal.


j) Tables


All tables must be cell-based and avoid using picture elements and text boxes. All tables should have a concise title and table in Arabic numerals. Footnotes can be used to explain abbreviations. Table should be clear enough to allow understanding without referring to the text. Number tables in the order of their mention in the text and references cited within a table should use numbers rather than author names.


k) Supplemental Data


Supplemental data are materials submitted for review and consideration for publication with the online version of the manuscript. Supplemental files should be uploaded with the initial submission, labeled appropriately, and cited within the manuscript as Table, Figure, Video with the prefix “Supp” (i.e Supp Table 1).


Supplemental table and figure legends should be included on the same pages as the tables and figures themselves. All supplemental data, including references, should be uploaded separately from the manuscript itself.


Manuscript submission


We accept only online submissions. The only corresponding author should submit manuscripts using the online manuscript submission system.  Please prepare your manuscript as one document with double spacing using the word-processing tool in Word (.doc, .docx, .rtf). Please use standard fonts (Arial, Times New Romance, Verdana with font size 11 or 12).


You can also submit the complete manuscript as one PDF (.pdf) file. To obtain one PDF file, you may use the manuscript file merger app located on the top right corner of your webpage. Please submit other documents (including supplemental material, if any) as separate files labeled appropriately. If you experience any technical difficulty, please contact us at admin@companyofscientists.com.


Mitochondrial and Metabolic Medicine is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Please do not submit any graphics that have been previously copyrighted unless you have obtained written permission from the copyright holder to publish under the CCAL license.


Manuscript Charges


There is no charge to submit a manuscript. M3 is fully Open Access, providing free access to all articles to readers worldwide. All manuscripts accepted for publication in M3 will be charged a publication fee of $500 which is substantially much less than other journals publishing similar manuscripts. Discounts are available to non-profit organizations and authors countries who are unable to pay.


Submission Preparation Checklist


As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.



  1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).

  2. The submission file is in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format.

  3. Where available, URLs for the references have been provided.

  4. The text is double-spaced; uses an 11 or 12-point font; employs italics, rather than underlining. The manuscript is one file and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.

  5. The text and references adhere to the bibliographic requirements outlined in the Author Guidelines.


Privacy Statement


The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.